NCT03012100: An overdue trial by Academic and Community Cancer Research United
This trial is overdue. It was due to report 2 years, 3 months ago.
Think we've made a mistake? Before contacting us, review the criteria in our paper. In particular, bear in mind the following:
- We can only rely on the structured data that sponsors put into the registry: they may enter incorrect or incomplete data.
- Reporting in a journal is not enough. The FDAAA rules state that the trial must be reported on ClinicalTrials.gov.
- Terminated trials are required to report results. Only withdrawn trials (which never recruited a single patient) are not.
Full data
| Full entry on ClinicalTrials.gov | NCT03012100 |
|---|---|
| Title | Double Blind, Parallel Groups, Controlled, Randomized Phase II Trial to Evaluate Vaccination With Folate Receptor Alpha Peptide Vaccine With GM-CSF as Vaccine Adjuvant Following Oral Cyclophosphamide Versus GM-CSF/Placebo to Prevent Recurrence in Patients With Triple Negative Breast Cancer |
| Results Status | Overdue |
| ACT or pACT? | This is what FDAAA officially calls an "Applicable Clinical Trial" |
| Start date | March 31, 2017 |
| Completion date | Aug. 30, 2022 |
| Required reporting date | Aug. 30, 2023, midnight |
| Actual reporting date | None |
| Date last checked at ClinicalTrials.gov | Dec. 5, 2025 |
| Days late | 828 |